Track topics on Twitter Track topics that are important to you
SBRT For Liver Cancer Before Liver Transplantation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest SBRT For Liver Cancer Before Liver Transplantation articles that have been published worldwide.
We have published hundreds of SBRT For Liver Cancer Before Liver Transplantation news stories on BioPortfolio along with dozens of SBRT For Liver Cancer Before Liver Transplantation Clinical Trials and PubMed Articles about SBRT For Liver Cancer Before Liver Transplantation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SBRT For Liver Cancer Before Liver Transplantation Companies in our database. You can also find out about relevant SBRT For Liver Cancer Before Liver Transplantation Drugs and Medications on this site too.
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related mortality in the US and a leading indication for liver transplantation (LT). Changes in chronic liver disease burden have led to aging of the chronic liver disease population, but how this affects patients with HCC is unknown. This study aims to characterize trends and transplant-associated outcomes among patients ≥65y listed for LT with HCC.
The combination of two-stage total hepatectomy and partial liver transplantation (LT) for secondary unresectable liver-only malignancies is producing a great quantity of literature. In the first stage, partial hepatectomy leaves a deportalised right liver while left-graft LT is performed. The second stage is scheduled after enough liver regeneration has occurred and consists of residual liver removal.
Liver transplantation (LT) is an option for people with liver failure who cannot be cured with other therapies and for some people with liver cancer.
Liver transplantation (LT) for patients with propionic acidaemia (PA) is an emerging therapeutic option.
Alcohol-associated liver disease (ALD) has become the commonest indication for liver transplantation (LT) in Western countries. For example, recent EASL guidelines indicate that about 40% of patients transplanted in 2016 had ALD as the primary indication for transplantation (including hepatocellular carcinoma). As transplantation for hepatitis C infection will significantly decrease in most countries, this percentage should continue to increase. This article is protected by copyright. All rights reserved.
Living donor liver transplantation (LDLT) is becoming an established procedure for treating patients with end-stage liver disease; however, small-for-size graft syndrome has been a major obstacle to this procedure.
We read with great interest the article recently published in Liver Transplantation by Ikegami and colleagues (1). This study compared the clinical results of patients with and without portal vein thrombosis (PVT) underwent liver transplantation (LT). We would like to share our opinion and criticisms about this valuable work as follows.
Racial and ethnic differences in the presentation and outcomes of patients waitlisted with acute liver failure (ALF) have not been explored.
Wilson Disease (WD) is a rare cause of acute liver failure (ALF) thought to have a uniformly fatal outcome without liver transplantation (LT). Previous studies proposed diagnostic and prognostic criteria for WD-ALF. It is not known whether these apply to WD patients presenting as severe acute liver injury (WD-ALI) without encephalopathy.
Although stereotactic body radiation therapy (SBRT) is an attractive non-invasive approach for liver irradiation, it presents specific challenges associated with respiration-induced liver motion, daily tumor localization due to liver deformation and poor visualization of target with respect to adjacent normal liver in CT. We aim to identify potential hazards and develop a set of mitigation strategies to improve the safety of our liver SBRT program, using failure mode and effect analysis (FMEA).
The need for liver transplantation (LT) among older patients is increasing, but the role of LT in the elderly (≥70 years) is not well defined. We retrospectively reviewed all primary LTs from 1998 through 2016 at our center. Survival and associated risk factors were analyzed with Cox regression and Kaplan-Meier methods for LT recipients in three age groups:
Active tuberculosis (TB) is a severe and potentially fatal complication of liver transplantation (1). The management of TB in liver transplant (LT) recipients is challenging not only because of the severity of this infection, but because first-line TB treatment is associated with significant hepatotoxicity and drug interactions.
Alcohol-related liver disease (ALD) is one of the main indications for liver transplantation (LT). Severe alcohol relapse can rapidly lead to recurrence of alcohol-related cirrhosis (RAC) on the graft. The aim of this study is to describe the natural history of RAC and overall survival after LT and after RAC diagnosis.
Wilson's disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end-stage liver disease, it has remained controversial in presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in Italy, focusing on disease phenotype at time of LT.
Combined liver- kidney transplantation (CLKT) in children is still a rarely performed procedure. Our aim was to analyze the effect of the simultaneous transplantation of the kidney in pediatric CLKT on the liver graft flow velocity, and vascular complications compared to singular liver transplantation (LTX) in children.
Cardiovascular disease (CVD) is a major contributor to long-term mortality after liver transplantation (LT) necessitating aggressive modification of CVD risk. However, it is unclear how coronary artery disease (CAD) and development dyslipidemia following LT impacts clinical outcomes and how management of these factors may impact survival.
Management of portal vein thrombosis (PVT), especially advanced PVT involving superior mesenteric vein (SMV), in living donor liver transplantation (LDLT) is challenging.
Obesity has become an epidemic in the United States over the past decade and recent studies have shown this trend in the liver transplant (LT) population. These patients may be candidates for laparoscopic sleeve gastrectomy (LSG) to promote significant and sustained weight loss to prevent recurrence of NASH, but safety remains a concern and efficacy in this setting is uncertain.
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor. Currently, liver transplantation may be the optimal treatment for HCC in cirrhotic patients. Patient selection is currently based on tumor size. We developed a program to offer liver transplantation to selected patients with HCC outside of traditional criteria.
Patients following liver transplantation are at risk to develop acute kidney injury (AKI). The aim of our study was to assess risk factors for the development of AKI and impact of AKI on the outcome of patients after liver transplantation (OLT).
As indicated by Groose et al article1, patients with advanced ESLD and high MELD score appear to be at risk of developing ICT. Higher MELD indicates a coagulation imbalance which can trigger unpredictably ICT. Under those circumstances, a prophylactic dose of heparin appears protective against ICT. This article is protected by copyright. All rights reserved.
Checkpoint inhibitor therapy has been a novel approach in a new wave of cancer treatments. Medications such as Pembrolizumab or Nivolumab have recently been approved for the treatment of several different types of malignancies. However, their safety in the treatment of cancers in liver transplant recipients is unfamiliar. Previous case reports have documented the development of allograft rejection in patients receiving these agents.
We read with great interest the recently published article by Ghinolfi et al entitled "Nonagenarian Grafts for Liver Transplantation" . This study compared the outcomes of 16 nonagenarian graft recipients to a matched control population and results showed no major differences across the two groups. Authors concluded that the use of old donors allowed to drastically reduce waitlist mortality and drop-out rate, supporting the hypothesis that no age cut-off should be applied to deceased donors, despite age...